Actuate Therapeutics Files S-1/A for U.S. IPO
Actuate Therapeutics, Inc. (SEC file no. 0001652935) filed an amended S-1 registration statement with the SEC on October 19, 2026, initiating its U.S. IPO process. The clinical-stage biotech plans to use proceeds for oncology-targeted therapy development and clinical trials.
51CFO view：Biotech IPOs require CFOs fluent in ASC 730 R&D accounting and FDA-aligned revenue recognition frameworks. If the CFO has China-based experience, the team must pre-prepare SEC Q&A documentation on cross-border work history and GAAP application consistency.
Actuate Therapeutics, Inc. (SEC file no. 0001652935) filed an amended S-1 registration statement with the SEC on October 19, 2026, initiating its U.S. IPO process. The clinical-stage biotech plans to use proceeds for oncology-targeted therapy development and clinical trials.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →